Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for Platinum-Resistant ovarian cancer: BD0801 combo trial completed

NCT ID NCT04908787

Disease control Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial tested whether adding the experimental drug BD0801 to standard chemotherapy can help women with recurrent ovarian cancer that no longer responds to platinum-based treatments. The study enrolled 421 participants and compared the combination to chemotherapy alone. The goal was to see if the drug could slow cancer growth and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
BD0801 (an anti-angiogenic drug) combined with chemotherapy (paclitaxel, topotecan, or liposomal doxorubicin)
What this could lead to
If successful, this combination could offer a new treatment option to slow cancer growth in patients with platinum-resistant ovarian cancer, where few effective therapies exist.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The benefit may be modest, and side effects from adding BD0801 to chemotherapy could include bleeding, high blood pressure, or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

421 people

The number who actually took part.

Started

Jun 2021

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * female patients, \>/=18 years of age; * epithelial ovarian, fallopian tube or primary peritoneal cancer; * platinum-resistant disease (disease progression within \<6 months of platinum therapy) * Eastern Cooperative Oncology Group（ECOG）performance status of 0-1 Exclusion Criteria: * non-epithelial tumours * ovarian tumours with low malignant potential * Received 1 line of systemic therapy for ovarian cancer following platinum resistance and/or \> 1 line of non-platinum systemic therapy prior to platinum resistance. * prior radiotherapy to the pelvis or abdomen

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

Contacts and locations

Locations

  • Affiliated Hospital of Jining Medical University

    Jining, Shandong, China

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, Sichuan, China

  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Cancer Hospital Chinese Academy Of Medical Sciences, Shenzhen Center

    Shenzhen, Guangdong, China

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China

  • Fukuang General Hospital of Liaoning Health Industry Group

    Fushun, Liaoning, China

  • Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute, Guangxi Cancer Hospital&Medical University School&Cancer Center

    Nanning, Guangxi, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • Hangzhou Cancer Hospital

    Hangzhou, Zhejiang, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Jiangxi Maternal and Child Health Hospital

    Nanchang, Jiangxi, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • Mianyang Central Hospital

    Mianyang, Sichuan, China

  • Nanjing Women and Children's Healthcare Hospital, Women's Hospital of Nanjing Medical University

    Nanjing, Jiangsu, China

  • Nantong Cancer Hospital

    Nantong, Jiangsu, China

  • Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Shandong Cancer Hospital & Institute

    Jinan, Shandong, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China

  • The First Affiliated Hospital of USTC West District,Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of University of South China

    Hengyang, Hunan, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The Second Hospital of Dalian Medical University

    Dalian, Liaoning, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second Norman Bethune Hospital of Jilin University

    Changchun, Jilin, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Tianjin Center Hospital of Gynecology Obstetrics

    Tianjin, Tianjin Municipality, China

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Xuzhou Central Hospital(Southeast University Affiliated Hospital)

    Xuzhou, Jiangsu, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.